Sangamo and Pfizer begin dosing in Phase I/II trial for haemophilia A

Sangamo Therapeutics and Pfizer have begun dosing patients in a Phase I/II clinical trial (Alta) of investigational gene therapy SB-525 to treat patients with a rare genetic blood disease known as haemophilia A.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news